News

January 31, 2020February 14, 2020

Stony Brook Team Given $4.2M Grant to Expand Promising Work in Advanced Prostate Cancer

News

Researchers at Stony Brook University have been awarded a five-year, $4.2 million grant from the National Cancer Institute (NCI) to expand work into promising therapeutic agents against metastatic prostate cancer. ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition known ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

News

A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — is able to overcome prostate cancer resistance to Xtandi ... Read more

January 24, 2020February 5, 2020

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests

News

Six regions in the non-coding parts of the DNA that surround FOXA1, a major prostate cancer driver, may be therapeutic targets for lowering the amount of this cancer-promoting protein — ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on preliminary ... Read more

January 22, 2020February 14, 2020

FDA OKs Phase 2b Trial on SUBA-Itraconazole for Metastatic Castration-resistant Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has cleared a Phase 2b clinical trial to evaluate the effects of combining SUBA-Itraconazole, an oral anti-fungal medication with anti-cancer properties, with chemotherapy ... Read more

January 22, 2020May 22, 2020

FDA Grants Priority Review to Lynparza as Treatment for Mutated Metastatic Castration-resistant Prostate Cancer

News

Note: This story was updated May 21, 2020, to note that Merck is known as MSD outside the U.S. and Canada, not as EMD Serono. The U.S. Food and Drug Administration ... Read more

January 20, 2020

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports

News

Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated and significantly reduces hot flashes in advanced prostate cancer patients using androgen deprivation therapy (ADT). These ... Read more

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review status ... Read more

January 15, 2020January 15, 2020

Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer

News

Advaxis is seeking permission from the U.S. Food and Drug Administration (FDA) to start the first Phase 1 clinical trial of ADXS-504, a potential immunotherapy for prostate cancer. Cancer cells ... Read more